Compare Sun Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs NOVARTIS - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA NOVARTIS SUN PHARMA/
NOVARTIS
 
P/E (TTM) x 28.3 493.6 5.7% View Chart
P/BV x 2.4 28.6 8.5% View Chart
Dividend Yield % 0.7 1.6 40.9%  

Financials

 SUN PHARMA   NOVARTIS
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
NOVARTIS
Mar-18
SUN PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs679758 89.6%   
Low Rs375579 64.8%   
Sales per share (Unadj.) Rs121.1228.4 53.0%  
Earnings per share (Unadj.) Rs13.431.7 42.1%  
Cash flow per share (Unadj.) Rs20.732.8 63.1%  
Dividends per share (Unadj.) Rs2.7510.00 27.5%  
Dividend yield (eoy) %0.51.5 34.9%  
Book value per share (Unadj.) Rs172.6297.1 58.1%  
Shares outstanding (eoy) m2,399.2624.69 9,717.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.42.9 148.6%   
Avg P/E ratio x39.421.1 187.1%  
P/CF ratio (eoy) x25.520.4 124.9%  
Price / Book Value ratio x3.12.2 135.7%  
Dividend payout %20.631.5 65.2%   
Avg Mkt Cap Rs m1,264,65016,505 7,662.1%   
No. of employees `00017.50.7 2,619.9%   
Total wages/salary Rs m59,6711,445 4,128.6%   
Avg. sales/employee Rs Th16,608.18,441.3 196.7%   
Avg. wages/employee Rs Th3,409.62,163.6 157.6%   
Avg. net profit/employee Rs Th1,833.81,173.1 156.3%   
INCOME DATA
Net Sales Rs m290,6595,639 5,154.6%  
Other income Rs m10,2551,718 596.8%   
Total revenues Rs m300,9147,357 4,090.1%   
Gross profit Rs m63,076-63 -100,921.4%  
Depreciation Rs m17,53325 69,298.4%   
Interest Rs m5,55355 10,040.7%   
Profit before tax Rs m50,2461,575 3,189.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,009792 759.1%   
Profit after tax Rs m32,093784 4,095.6%  
Gross profit margin %21.7-1.1 -1,957.9%  
Effective tax rate %12.050.3 23.8%   
Net profit margin %11.013.9 79.5%  
BALANCE SHEET DATA
Current assets Rs m310,6929,522 3,263.1%   
Current liabilities Rs m173,3963,296 5,260.8%   
Net working cap to sales %47.2110.4 42.8%  
Current ratio x1.82.9 62.0%  
Inventory Days Days9937 270.5%  
Debtors Days Days11228 392.5%  
Net fixed assets Rs m232,47746 505,384.6%   
Share capital Rs m2,399123 1,944.3%   
"Free" reserves Rs m411,6917,213 5,707.6%   
Net worth Rs m414,0917,336 5,644.3%   
Long term debt Rs m15,2260-   
Total assets Rs m646,93811,105 5,825.5%  
Interest coverage x10.029.5 34.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.40.5 88.5%   
Return on assets %5.87.6 77.0%  
Return on equity %7.810.7 72.6%  
Return on capital %10.222.2 45.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,02561 108,952.8%   
Fx outflow Rs m38,6103,630 1,063.6%   
Net fx Rs m27,415-3,570 -768.0%   
CASH FLOW
From Operations Rs m21,9651,610 1,364.3%  
From Investments Rs m-6,813687 -991.6%  
From Financial Activity Rs m-27,305-2,677 1,020.2%  
Net Cashflow Rs m-8,442-380 2,223.8%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.1 2.0 256.5%  
FIIs % 23.0 1.6 1,437.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 21.5 38.6%  
Shareholders   133,026 41,647 319.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   WYETH LTD  IPCA LABS  NATCO PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend, Developments From the IPO Space, and Top Cues in Focus Today(Pre-Open)

On Tuesday, Indian share markets fell sharply during closing hours amid fears of rising crude oil prices and weakness in the rupee.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 17, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS